Article
Multidisciplinary Sciences
Laura Sole, Teresa Lobo-Jarne, Daniel Alvarez-Villanueva, Josune Alonso-Maranon, Yolanda Guillen, Marta Guix, Irene Sangrador, Catalina Rozalen, Anna Vert, Antonio Barbachano, Joan Lop, Marta Salido, Beatriz Bellosillo, Raquel Garcia-Romero, Marta Garrido, Jessica Gonzalez, Maria Martinez-Iniesta, Erika Lopez-Arribillaga, Ramon Salazar, Clara Montagut, Ferran Torres, Mar Iglesias, Toni Celia-Terrassa, Alberto Munoz, Alberto Villanueva, Anna Bigas, Lluis Espinosa
Summary: This study reveals that sub-lethal dose of chemotherapy induces a quiescence-like phenotype and a YAP-dependent fetal-like intestinal stem cell state in wild-type p53 colorectal cancers, which is associated with higher metastatic activity and poor prognosis in patients.
NATURE COMMUNICATIONS
(2022)
Article
Biotechnology & Applied Microbiology
Tianyi Ma, Tianyu Qiao, Ziming Yuan, Guiyu Wang, Rui Huang, Meng Wang, Hanqing Hu, Yihao Zhu, Xiaoming Zou, Xishan Wang
Summary: JAKMIP2-AS1 is significantly upregulated in colorectal cancer tissues, promoting cell proliferation and associated with poor prognosis. Inhibition of JAKMIP2-AS1 by RNAi decreases cell proliferation and hinders cell growth.
ONCOTARGETS AND THERAPY
(2021)
Article
Pathology
Ding-Ping Sun, Chia-Chun Wu, Chia-Lin Chou, Li-Chin Cheng, Wen-Ching Wang, Shiau-Shiuan Lin, Shih-Ting Hung, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin
Summary: The study investigates the correlation between NCAPG and CRC prognosis, as well as its function in CRC cells. The overexpression of NCAPG is positively correlated with clinicopathologic characteristics and negatively correlated with disease-free survival and overall survival. Knockdown of NCAPG inhibits the proliferation, migration, and invasion of CRC cells, and interferes with G2/M-G1 transition in the cell cycle, leading to inhibited cell proliferation. NCAPG may serve as a candidate biomarker for CRC prognosis and a potential therapeutic target for CRC.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Oncology
Linxi Zhang, Xiaowen Xu, Yamin Pan, Fuao Cao
Summary: High expression of SH2B1 in colorectal cancer is associated with unfavorable prognosis and poor chemotherapeutic response.
Article
Oncology
Daoli Liu, Xubing Zhang, Hong Zhou, Zhiqiang Zhu, Yiren He, Xiao Wan, Bo Zhang, Shaojun Liu, Liu Liu
Summary: This study aimed to evaluate the impact of type 2 diabetes mellitus (T2DM) on the short-term outcomes and long-term survival of patients with colorectal cancer (CRC) who underwent curative resection. The results showed that patients with T2DM had more complications after surgery, longer hospitalization time, and worse prognosis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Takuya Shiraishi, Koji Ikeda, Yuichiro Tsukada, Yuji Nishizawa, Takeshi Sasaki, Masaaki Ito, Motohiro Kojima, Genichiro Ishii, Ryo Tsumura, Sinji Saijou, Yoshikatsu Koga, Masahiro Yasunaga, Yasuhiro Matsumura
Summary: TMEM180 is a useful marker for clinical prognosis in patients with colorectal cancer, with high expression levels associated with significantly higher cancer specific survival rates. Additionally, in vitro and in vivo experiments suggest a positive correlation between TMEM180 expression and tumorigenic activity in CRC. Further studies on TMEM180 and its monoclonal antibody are warranted for potential development of therapeutics against CRC.
Article
Immunology
Siyuan Weng, Zaoqu Liu, Xiaofeng Ren, Hui Xu, Xiaoyong Ge, Yuqing Ren, Yuyuan Zhang, Qin Dang, Long Liu, Chunguang Guo, Richard Beatson, Jinhai Deng, Xinwei Han
Summary: The study identified that the SCG2 gene is closely associated with the chemotherapy response in colorectal cancer patients, with high expression predicting poorer prognosis and showing significantly higher expression in the APC non-mutation group. The SCG2 high expression subgroup is more suitable for immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Karla Montalban-Hernandez, Ramon Cantero-Cid, Roberto Lozano-Rodriguez, Alejandro Pascual-Iglesias, Jose Avendano-Ortiz, Jose Carlos Casalvilla-Duenas, Gloria Cristina Bonel Perez, Jenny Guevara, Cristobal Marcano, Cristina Barragan, Jaime Valentin, Carlos del Fresno, Luis Augusto Aguirre, Eduardo Lopez Collazo
Summary: Among colorectal cancer patients, the level of soluble SIGLEC5 may serve as a potential prognostic marker and predictor of patient outcomes.
Article
Gastroenterology & Hepatology
Jia-Jia Liu, Fang He, Shi-Bin Guo
Summary: The study aimed to investigate the relationship between TMEM16A and clinicopathological features and prognosis in patients with colorectal cancer (CRC). The results showed that the expression of TMEM16A was significantly associated with tumor invasion, lymph node metastasis, and Dukes stage in CRC. High expression of TMEM16A could serve as an independent predictor for poor prognosis in CRC patients.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
(2022)
Review
Oncology
Nishant Thakur, Muhammad Joan Ailia, Yosep Chong, Ok Ran Shin, Kwangil Yim
Summary: This study evaluated the prognostic significance, clinicopathological value, and relationship with epithelial-mesenchymal transition (EMT) of tumor budding (TB) in lung cancer. The results showed that high-grade TB was significantly associated with poor overall survival (OS) and disease-free survival (DFS), as well as clinicopathological characteristics and EMT markers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Junhong Shi, Meiyu Bao, Weifeng Wang, Xuan Wu, Yueying Li, Changdong Zhao, Weiwei Liu
Summary: PLOD3 is highly expressed in colorectal cancer and associated with advanced stage CRC and poor survival. High PLOD3 expression is correlated with low levels of immune cells such as B cells, CD4(+) T cells, M1 macrophages, and CD8(+) T cells. Patients with high PLOD3 expression may be resistant to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Anatomy & Morphology
Xiangwen Zhang, Jiaming Xue, Huiliang Yang, Tingting Zhou, Guo Zu
Summary: TNFAIP6 plays an important role in the prognosis of gastric cancer patients, with higher expression levels associated with tumor invasion depth, lymph node metastasis, TNM stage, and poorer overall survival. Knockdown of TNFAIP6 inhibited proliferation, invasion, and metastasis of gastric cancer cells in vitro.
Review
Oncology
Muhammad Joan Ailia, Nishant Thakur, Yosep Chong, Kwangil Yim
Summary: This study investigated the role of tumor budding (TB) in gynecological cancers and found that TB is associated with poor survival outcomes. TB is related to epithelial-mesenchymal transition, microvessel density, and decreased hormone receptor expression. TB can be used as a poor prognostic marker for gynecologic cancers.
Article
Pharmacology & Pharmacy
Guanyu Yu, Mengnan Xu, Leqi Zhou, Kuo Zheng, Xiaoming Zhu, Jinke Sui, Cheng Xin, Wenjun Chang, Wei Zhang, Fuao Cao
Summary: This study investigated the expression of phosphorylated Focal adhesion kinase (p-FAK) in colorectal cancer (CRC) and its association with prognosis. The results showed that high p-FAK expression was associated with poor prognosis and poor chemotherapeutic response in CRC. Therefore, the expression level of p-FAK can serve as an independent prognostic biomarker for CRC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Huifang Liu, Jing Wu, Xiaoyu Xu, Han Wang, Changhua Zhang, Songcheng Yin, Yulong He
Summary: The study revealed that the infiltrated levels of TIGIT(+)CD20(+) B cells around tumors in gastric cancer patients were associated with clinical outcomes and could potentially impact the exhaustion of CD8(+) T cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Leonard Depotte, Juliette Palle, Cosimo Rasola, Chloe Broudin, Vlad-Adrian Afrasanie, Antoine Mariani, Aziz Zaanan
Summary: Advanced gastric adenocarcinoma is a disease with poor prognosis. In recent years, new drugs, such as trastuzumab for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel, and trifluridine-tipiracil, have improved patient survival. Other drugs, including monoclonal antibodies and targeted therapies, are also being evaluated.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2024)